# Ni-Catalyzed Enantioselective Reductive Aryl-Alkenylation of Alkenes: Application to the Synthesis of (+)-Physovenine and (+)-Physostigmine

Yuxiu Li,<sup>‡</sup> Zhengtian Ding,<sup>‡</sup> Aiwen Lei\* and Wangqing Kong\*

The College of Chemistry and Molecular Sciences, Institute for Advanced Studies (IAS), College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, P. R. China

# Content

1. General information	S3
2. General procedures	S4
3. Additional experiments	S6
4. Characterization data of products	S7
5. Synthetic Applications	S48
6. Copies of the <sup>1</sup> H, <sup>19</sup> F and <sup>13</sup> C NMR spectra	S50
7. References	S86

#### 1. General Information

<sup>1</sup>H and <sup>13</sup>C NMR data were recorded with Bruker ADVANCE III (400 MHz) or JNM-ECZ400S/L1 (400 MHz) spectrometers. Chemical shifts are given in ppm. The spectra are calibrated to the residual <sup>1</sup>H and <sup>13</sup>C signals of the solvents. Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), doublet-doublet (dd), quintet (quint), septet (sept), multiplet (m), and broad (b). <sup>19</sup>F NMR spectra were recorded using CFCl<sub>3</sub> as internal standard. Gas chromatography were determined with a Varian GC 2000 gas chromatography instrument with a FID detector. High-resolution mass spectra (HRMS) were recorded on DIONEX UltiMate 3000 & Bruker Compact TOF mass spectrometer. Enantiomeric excesses were determined with a SHIMADZU LC-20ADXR system using chiral stationary phase columns (DAICEL) by comparing the samples with the corresponding racemic samples. Column and elution details were specified in each entry.

**Materials and Methods:** Unless otherwise stated, starting materials were purchased from commercial suppliers (Adamas-beta<sup>®</sup>, Alfa, Aldrich and so on). All reactions dealing with air- or moisture-sensitive compounds were performed in the argon-filled glove box or by standard Schlenk techniques in oven-dried reaction vessels under argon atmosphere. Solvents were purchased in HPLC quality, degassed by purging thoroughly with nitrogen and dried over activated molecular sieves of appropriate size. More sensitive compounds were stored in a desiccator or in a glove-box if required. Reactions were monitored by thin layer chromatography (TLC) using glass 0.25 mm silica gel plates. Compounds were visualized by UV-light at 254 nm and by dipping the plates in an aqueous potassium permanganate solution followed by heating. Flash column chromatography was performed over silica gel (200-400 mesh).

### 2. General Procedures

#### 2.1 General Procedure for Racemic Aryl-Alkenylation Reaction:



To a mixture of **1** (0.1 mmol), NiBr<sub>2</sub> (10 mol%), L**1** (20 mol%), Mn (3 equiv), MgCl<sub>2</sub> (4 equiv) and dry DMSO (2 mL) in a sealed tube was added alkenyl bromide **2** (0.3 mmol) under Argon. The reaction mixture was heated at 60 °C until the reaction was complete (monitored by TLC). The resulting mixture was quenched with sat. NH<sub>4</sub>Cl solution (5 mL) and further diluted with water (10 mL). The aqueous layer was extracted with EtOAc (3 x 15 mL) and the combined organic layers were washed with brine (2 x 20 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:40~1:5 (v/v) to afford the desired product **3**.

#### 2.2 General Procedure for Asymmetric Aryl-Alkenylation Reaction:



To a mixture of **1** (0.1 mmol), Ni(COD)<sub>2</sub> (10 mol%), **L15** (20 mol%), Zn (3 equiv) and dry DMA (2 mL) in a sealed tube was added alkenyl bromide **2** (0.3 mmol) under Argon. The reaction mixture was heated at room temperature until the reaction was complete (monitored by TLC). The resulting mixture was quenched with sat. NH<sub>4</sub>Cl solution (5 mL) and further diluted with water (10 mL). The aqueous layer was extracted with

EtOAc (3 x 15 mL) and the combined organic layers were washed with brine (2 x 20 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1:40~1:5 (v/v) to afford the desired product **3**.

# 3. Additional experiments

L1

17





<sup>a</sup>Reactions were carried out with **1a** (0.1 mmol), **2a** (0.3 mmol), NiBr<sub>2</sub> (10 mol%), ligand (20 mol%), Mn (0.3 mmol), MgCl<sub>2</sub> (0.4 mmol) in 2 mL solvent at 60 °C for 12 h, unless noted otherwise. <sup>b</sup>Isolated yields. <sup>c</sup>Without NiBr<sub>2</sub>.

\_

DMSO

0

## 4. Characterization data of products

(E)-3-(3-(4-Methoxyphenyl)allyl)-1,3-dimethylindolin-2-one (3aa)

Me OMe Me Chemical Formula: C<sub>20</sub>H<sub>21</sub>NO<sub>2</sub> Exact Mass: 307.1572

**3aa** was prepared according to general procedure 2.1 using **1a** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3aa** as yellow oil (90% yield). The <sup>1</sup>H NMR data matched those reported in the literature:<sup>1</sup> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.29-7.24 (m, 1H), 7.22 (dd, *J* = 7.3, 0.7 Hz, 1H), 7.16-7.10 (m, 2H), 7.07 (td, *J* = 7.5, 0.9 Hz, 1H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.80-6.75 (m, 2H), 6.29 (d, *J* = 15.7 Hz, 1H), 5.74 (ddd, *J* = 15.5, 8.0, 7.1 Hz, 1H), 3.77 (s, 3H), 3.18 (s, 3H), 2.70-2.52 (m, 2H), 1.41 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.3, 158.8, 143.1, 133.6, 133.0, 130.0, 127.7, 127.2, 122.9, 122.3, 121.8, 113.7, 107.9, 55.2, 48.7, 41.6, 26.1, 22.4.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 6.7 min (minor), 8.0 min (major).

Optical Rotation:  $[\alpha]_D^{33}$  +4.6 (*c* 0.2, <sup>*i*</sup>PrOH) for 82% ee.



(*E*)-3-(3-(4-Methoxyphenyl)allyl)-1,3,5-trimethylindolin-2-one (**3ba**)



**3ba** was prepared according to general procedure 2.2 using **1b** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ba** as yellow oil (81% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.16-7.09 (m, 2H), 7.08-7.02 (m, 2H), 6.81-6.74 (m, 2H), 6.70 (d, *J* = 7.8 Hz, 1H), 6.29 (d, *J* = 15.7 Hz, 1H), 5.77-5.66 (m, 1H), 3.77 (s, 3H), 3.15 (s, 3H), 2.61 (dd, *J* = 7.6, 1.0 Hz, 2H), 2.35 (s, 3H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 158.8, 140.8, 133.7, 132.9, 131.8, 130.2, 127.9, 127.2, 123.8, 122.1, 113.8, 107.6, 55.2, 48.7, 41.7, 26.1, 22.5, 21.2; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 322.1802; found 322.1795.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 6.3 min (minor), 7.2 min (major).

Optical Rotation: [α]<sub>D</sub><sup>32</sup> +38.0 (*c* 0.5, <sup>*i*</sup>PrOH) for 90% ee.



(E)-5-Methoxy-3-(3-(4-methoxyphenyl)allyl)-1,3-dimethylindolin-2-one (3ca)



**3ca** was prepared according to general procedure 2.1 using **1c** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ca** as yellow oil (67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.17-7.09 (m, 2H), 6.85 (d, *J* = 2.4 Hz, 1H), 6.81-6.75 (m, 3H), 6.72 (d, *J* = 8.4 Hz, 1H), 6.30 (d, *J* = 15.7 Hz, 1H), 5.73 (dt, *J* = 15.5, 7.5 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.15 (s, 3H), 2.62 (dd, *J* = 7.5, 1.0 Hz, 2H), 1.40 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.9, 158.8, 155.8, 136.7, 135.0, 133.0, 130.0, 127.2, 121.8, 113.7, 111.6, 110.6, 108.1, 55.8, 55.2, 49.1, 41.6, 26.2, 22.6; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>3</sub><sup>+</sup>[M+H]<sup>+</sup> 338.1751; found 338.1743.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 8.4 min (minor), 10.4 min (major).

Optical Rotation:  $[\alpha]_D^{33}$  +51.6 (*c* 0.2, <sup>*i*</sup>PrOH) for 80% ee.



(E)-5-Fluoro-3-(3-(4-methoxyphenyl)allyl)-1,3-dimethylindolin-2-one (3da)



**3da** was prepared according to general procedure 2.2 using **1d** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3da** as yellow oil (74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.17-7.11 (m, 2H), 7.00-6.92 (m, 2H), 6.82-6.75 (m, 2H), 6.73 (dt, *J* = 8.3, 3.3 Hz, 1H), 6.30 (t, *J* = 13.5 Hz, 1H), 5.70 (dt, *J* = 15.5, 7.6 Hz, 1H), 3.78 (s, 3H), 3.17 (s, 3H), 2.70-2.53 (m, 2H), 1.39 (d, *J* = 11.8 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.9, 159.2 (d, *J* = 240.3 Hz), 158.9, 139.0, 135.3 (d, *J* = 7.8 Hz), 133.3, 129.8, 127.3, 121.3, 113.9 (d, *J* = 21.8 Hz), 113.8, 111.1 (d, *J* = 24.6 Hz), 108.3 (d, *J* = 8.1 Hz), 55.2, 49.2, 41.6, 26.3, 22.5; <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>)  $\delta$  -120.83; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>21</sub>FNO<sub>2</sub>+[M+H]<sup>+</sup> 326.1551; found 326.1550.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 7.0 min (minor), 8.2 min (major).

Optical Rotation:  $[\alpha]_D^{32}$  +3.7 (*c* 0.5, <sup>*i*</sup>PrOH) for 89% ee.









(E)-3-(3-(4-Methoxyphenyl)allyl)-1,3-dimethyl-5-(trifluoromethyl)indolin-2-one (3ea)



**3ea** was prepared according to general procedure 2.1 using **1e** and **2a** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3ea** as yellow oil (67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.55 (dd, *J* = 8.1, 0.9 Hz, 1H), 7.45 (d, *J* = 1.1 Hz, 1H), 7.15-7.08 (m, 2H), 6.88 (d, *J* = 8.2 Hz, 1H), 6.82-6.74 (m, 2H), 6.28 (d, *J* = 15.7 Hz, 1H), 5.67 (dt, *J* = 15.5, 7.6 Hz, 1H), 3.77 (s, 3H), 3.20 (s, 3H), 2.65 (dd, *J* = 7.6, 1.0 Hz, 2H), 1.44 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 159.0, 146.2, 134.2, 133.8, 129.8, 127.3, 126.1 (d, *J* = 58.0 Hz), 125.7 (q, *J* = 4.1 Hz), 124.6 (d, *J* = 32.6 Hz), 120.9, 119.9 (q, *J* = 3.6 Hz), 113.9, 107.7, 55.3, 48.8, 41.6, 26.4, 22.4; <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>)  $\delta$  -61.27; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>2</sub>+[M+H]+ 376.1519; found 376.1525.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 5.3 min (minor), 5.8 min (major).

Optical Rotation:  $[\alpha]_D^{34}$  +17.6 (c 0.5, <sup>*i*</sup>PrOH) for 82% ee.



(*E*)-3-(3-(4-Methoxyphenyl)allyl)-1,3,6-trimethylindolin-2-one (**3fa**)



**3fa** was prepared according to general procedure 2.1 using **1f** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3fa** as yellow oil (64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.15 (d, *J* = 8.7 Hz, 2H), 7.10 (d, *J* = 7.5 Hz, 1H), 6.87 (d, *J* = 7.4 Hz, 1H), 6.78 (t, *J* = 5.8 Hz, 2H), 6.65 (s, 1H), 6.29 (d, *J* = 15.7 Hz, 1H), 5.76 (ddd, *J* = 15.5, 8.0, 7.1 Hz, 1H), 3.78 (s, 3H), 3.16 (s, 3H), 2.70-2.48 (m, 2H), 2.38 (s, 3H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.6, 158.8, 143.1, 137.8, 132.9, 130.7, 130.1, 127.2, 122.8, 122.7, 122.1, 113.7, 108.9, 55.2, 48.4, 41.6, 26.1, 22.6, 21.8; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 322.1802; found 322.1804. (E)-6-chloro-3-(3-(4-methoxyphenyl)allyl)-1,3-dimethylindolin-2-one (**3ga**)



**3ga** was prepared according to general procedure 2.2 using **1g** and **2a** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3ga** as yellow oil (44% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.17-7.10 (m, 3H), 7.03 (dd, *J* = 7.9, 1.8 Hz, 1H), 6.81 (d, *J* = 1.8 Hz, 1H), 6.80-6.76 (m, 2H), 6.28 (d, *J* = 15.7 Hz, 1H), 5.70 (dt, *J* = 15.4, 7.6 Hz, 1H), 3.78 (s, 3H), 3.16 (s, 3H), 2.68-2.49 (m, 2H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 159.0, 144.3, 133.5, 133.4, 131.9, 129.8, 127.3, 123.8, 122.1, 121.3, 113.8, 108.7, 55.3, 48.5, 41.5, 26.2, 22.5; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>21</sub>CINO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 342.1255; found 342.1253.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 6.6 min (minor), 6.9 min (major).

Optical Rotation:  $[\alpha]_D^{33}$  +7.9 (*c* 0.2, <sup>*i*</sup>PrOH) for 85% ee.





(E)-6-Methoxy-3-(3-(4-methoxyphenyl)allyl)-1,3-dimethylindolin-2-one (3ha)



**3ha** was prepared according to general procedure 2.1 using **1h** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ha** as yellow oil (74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.18-7.12 (m, 2H), 7.10 (d, *J* = 8.1 Hz, 1H), 6.82-6.75 (m, 2H), 6.56 (dd, *J* = 8.1, 2.3 Hz, 1H), 6.41 (d, *J* = 2.3 Hz, 1H), 6.29 (d, *J* = 15.8 Hz, 1H), 5.80-5.68 (m, 1H), 3.82 (s, 3H), 3.77 (s, 3H), 3.15 (s, 3H), 2.67-2.50 (m, 2H), 1.38 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.8, 159.8, 158.8, 144.3, 132.9, 130.1, 127.2, 125.6, 123.4, 122.1, 113.7, 106.0, 96.0, 55.5, 55.2, 48.2, 41.8, 26.1, 22.6; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>3</sub>+[M+H]<sup>+</sup> 338.1751; found 338.1747.

(E)-3-(3-(4-Methoxyphenyl)allyl)-1,3,7-trimethylindolin-2-one (**3ia**)

Chemical Formula: C<sub>21</sub>H<sub>23</sub>NO<sub>2</sub> Exact Mass: 321.1729

**3ha** was prepared according to general procedure 2.1 using **1h** and **2a** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3ha** as yellow oil (63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.19-7.10 (m, 2H), 7.06 (dd, *J* = 6.9, 1.4 Hz, 1H), 7.01-6.90 (m, 2H), 6.82-6.75 (m, 2H), 6.28 (d, *J* = 15.7 Hz, 1H), 5.73 (dt, *J* = 15.5, 7.5 Hz, 1H), 3.78 (s, 3H), 3.46 (s, 3H), 2.63-2.58 (m, 2H), 2.56 (s, 3H), 1.38 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  181.0, 158.8, 140.84 134.3, 132.9, 131.5, 130.1, 127.3, 122.2, 122.1, 120.8, 119.5, 113.8, 55.2, 47.9, 41.9, 29.5, 22.9, 19.1; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 322.1802; found 322.1809.

(*E*)-1-(3-(4-Methoxyphenyl)allyl)-1,8-dimethyl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-2(1H)-one (**3ja**)



**3ja** was prepared according to general procedure 2.1 using **1j** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ja** as yellow oil (74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.14 (t, *J* = 5.7 Hz, 2H), 6.85 (d, *J* = 16.4 Hz, 2H), 6.81-6.75 (m, 2H), 6.30 (d, *J* = 15.8 Hz, 1H), 5.78 (dt, *J* = 15.4, 7.5 Hz, 1H), 3.77 (s, 3H), 3.65 (td, *J* = 6.8, 4.7 Hz, 2H), 2.70 (t, *J* = 6.0 Hz, 2H), 2.65-2.50 (m, 2H), 2.32 (s, 3H), 2.03-1.80 (m, 2H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.0, 158.8, 136.4, 132.8, 132.2, 131.3, 130.2, 127.2, 126.9, 122.3, 121.6, 119.7, 113.8, 55.2, 50.1, 41.4, 38.7, 24.5, 22.1, 21.4, 21.4; HRMS: (ESI) calcd for C<sub>23</sub>H<sub>26</sub>NO<sub>2</sub>+[M+H]<sup>+</sup> 348.1958; found 348.1953.

(*E*)-3-(3-(4-Methoxyphenyl)allyl)-1,3-dimethyl-1,3-dihydro-2*H*-pyrrolo[2,3-*b*]pyridin-2-one (**3ka**)

**3ka** was prepared according to general procedure 2.1 using **1k** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ka** as yellow oil (89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.17 (dd, *J* = 5.3, 1.5 Hz, 1H), 7.43 (dd, *J* = 7.2, 1.5 Hz, 1H), 7.15 (t, *J* = 5.7 Hz, 2H), 6.95 (dd, *J* = 7.2, 5.3 Hz, 1H), 6.82-6.76 (m, 2H), 6.30 (d, *J* = 15.7 Hz, 1H), 5.77 (dt, *J* = 15.5, 7.6 Hz, 1H), 3.78 (s, 3H), 3.28 (s, 3H), 2.73-2.52 (m, 2H), 1.43 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.9, 159.0, 156.6, 146.7, 133.7, 130.4, 129.7, 128.0, 127.3, 120.9, 117.9, 113.9, 55.3, 48.3, 41.1, 25.3, 21.9; HRMS: (ESI) calcd for C<sub>19</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>+[M+H]+ 305.1598; found 309.1593.

(E)-3-Hexyl-3-(3-(4-methoxyphenyl)allyl)-1-methylindolin-2-one (**3**Ia)



**3Ia** was prepared according to general procedure 2.1 using **1I** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3Ia** as yellow oil (82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.29-7.22 (m, 1H), 7.19 (d, *J* = 7.3 Hz, 1H), 7.15-7.03 (m, 3H), 6.79 (dd, *J* = 15.0, 8.2 Hz, 3H), 6.26 (d, *J* = 15.7 Hz, 1H), 5.70 (dt, *J* = 15.5, 7.5 Hz, 1H), 3.77 (s, 3H), 3.17 (s, 3H), 2.71-2.53 (m, 2H), 1.95 (td, *J* = 12.8, 4.6 Hz, 1H), 1.81 (td, *J* = 12.8, 4.4 Hz, 1H), 1.32-1.06 (m, 7H), 1.03-0.89 (m, 1H), 0.80 (t, *J* = 7.0 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.7, 158.8, 143.8, 132.8, 132.0, 130.1, 127.6, 127.2, 123.0, 122.3, 121.9, 113.7, 107.8, 55.2, 53.4, 41.4, 36.8, 31.5, 29.4, 26.0, 24.2, 22.5, 14.0; HRMS: (ESI) calcd for C<sub>25</sub>H<sub>32</sub>NO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 378.2428; found 378.2427.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 6.2 min (minor), 7.0 min (major).

Optical Rotation:  $[\alpha]_D^{35}$  +3.8 (c 0.5, <sup>*i*</sup>PrOH) for 80% ee.



(E)-3-Isopropyl-3-(3-(4-methoxyphenyl)allyl)-1-methylindolin-2-one (3ma)



Chemical Formula: C<sub>22</sub>H<sub>25</sub>NO<sub>2</sub> Exact Mass: 335.1885

**3ma** was prepared according to general procedure 2.1 using **1m** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ma** as yellow oil (55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.29-7.21 (m, 2H), 7.06 (ddd, *J* = 7.6, 4.6, 1.6 Hz, 3H), 6.78 (d, *J* = 7.6 Hz, 1H), 6.76-6.70 (m, 2H), 6.24 (d, *J* = 15.7 Hz, 1H), 5.66-5.53 (m, 1H), 3.75 (s, 3H), 3.14 (s, 3H), 2.73 (dddd, *J* = 13.5, 9.1, 7.5, 1.0 Hz, 2H), 2.25 (hept, *J* = 6.8 Hz, 1H), 0.99 (d, *J* = 6.9 Hz, 3H), 0.77 (d, *J* = 6.8 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.4, 158.7, 144.1, 132.5, 130.9, 130.2, 127.6, 127.1, 123.7, 122.2, 122.0, 113.7, 107.6, 56.6, 55.2, 38.7, 34.6, 25.8, 17.4, 17.3; HRMS: (ESI) calcd for C<sub>22</sub>H<sub>26</sub>NO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 336.1958; found 336.1956.

(*E*)-3-Benzyl-3-(3-(4-methoxyphenyl)allyl)-1-methylindolin-2-one (**3na**)



**3na** was prepared according to general procedure 2.1 using **1n** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3na** as yellow oil (82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.22 (dd, *J* = 7.3, 0.7 Hz, 1H), 7.19-7.14 (m, 1H), 7.14-7.10 (m, 2H), 7.08-6.98 (m, 4H), 6.85 (dd, *J* = 7.2, 2.2 Hz, 2H), 6.81-6.72 (m, 2H), 6.56 (d, *J* = 7.7 Hz, 1H), 6.33 (d, *J* = 15.7 Hz, 1H), 5.80-5.66 (m, 1H), 3.76 (s, 3H), 3.20 (d, *J* = 13.0 Hz, 1H), 3.09 (d, *J* = 13.0 Hz, 1H), 2.93 (s, 3H), 2.86-2.74 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  178.7, 158.8, 143.6, 135.9, 133.1, 130.7, 130.0, 129.8, 127.8, 127.5, 127.3, 126.3, 123.8, 121.9, 121.7, 113.7, 107.7, 55.2, 54.8, 43.1, 40.5, 25.8; HRMS: (ESI) calcd for C<sub>26</sub>H<sub>26</sub>NO<sub>2</sub>+[M+H]+ 384.1958; found 384.1962.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 9.9 min (major), 10.4 min (minor).

Optical Rotation:  $[\alpha]_D^{32}$  -9.8 (c 0.5, <sup>*i*</sup>PrOH) for 76% ee.





peak number

retention time

area

height

(E)-3-(Methoxymethyl)-3-(3-(4-methoxyphenyl)allyl)-1-methylindolin-2-one (**3oa**)



**30a** was prepared according to general procedure 2.1 using **10** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **30a** as yellow oil (63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.32 (dd, *J* = 7.3, 0.7 Hz, 1H), 7.30-7.26 (m, 2H), 7.16-7.04 (m, 3H), 6.86-6.72 (m, 3H), 6.29 (d, *J* = 15.7 Hz, 1H), 5.69 (ddd, *J* = 15.5, 8.2, 7.0 Hz, 1H), 3.77 (s, 3H), 3.72 (q, *J* = 9.0 Hz, 2H), 3.25 (d, *J* = 4.8 Hz, 3H), 3.22 (d, *J* = 3.4 Hz, 1H), 3.18 (s, 3H), 2.72 (ddd, *J* = 13.5, 6.9, 1.2 Hz, 1H), 2.61 (ddd, *J* = 13.6, 8.2, 0.8 Hz, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  177.9, 158.8, 143.9, 133.1, 130.6, 129.9, 128.1, 127.2, 123.4, 122.3, 121.0, 113.7, 107.9, 76.1, 59.5, 55.2, 54.0, 37.5, 26.2; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>24</sub>NO<sub>3</sub>+[M+H]+ 338.1751; found 338.1752.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 9.9 min (major), 10.7 min (minor).

Optical Rotation:  $[\alpha]_D^{34}$  +5.6 (*c* 0.5, <sup>*i*</sup>PrOH) for 89% ee.



(*E*)-1-Benzyl-3-(3-(4-methoxyphenyl)allyl)-3-methylindolin-2-one (**3pa**)



**3pa** was prepared according to general procedure 2.1 using **1p** and **2a** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3pa** as yellow oil (84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.28-7.22 (m, 1H), 7.12 (ddd, *J* = 18.0, 11.9, 5.0 Hz, 6H), 7.04 (td, *J* = 7.6, 1.0 Hz, 1H), 6.99 (t, *J* = 7.6 Hz, 2H), 6.82-6.74 (m, 2H), 6.35 (d, *J* = 15.8 Hz, 1H), 5.74-5.54 (m, 1H), 5.17 (d, *J* = 15.8 Hz, 1H), 4.60 (d, *J* = 15.8 Hz, 1H), 3.79 (s, 3H), 2.85-2.59 (m, 2H), 1.48 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.3, 158.9, 142.3, 135.7, 133.5, 133.2, 130.0, 128.7, 127.8, 127.4, 127.3, 127.0, 122.9, 122.5, 121.9, 113.8, 109.2, 55.3, 49.0, 43.7, 42.0, 23.4; HRMS: (ESI) calcd for C<sub>26</sub>H<sub>26</sub>NO<sub>2</sub><sup>+</sup>[M+H]<sup>+</sup> 384.1958; found 384.1959.

(*E*)-3-Cinnamyl-1,3-dimethylindolin-2-one (**3ab**)



Chemical Formula: C<sub>19</sub>H<sub>19</sub>NO Exact Mass: 277.1467

**3ab** was prepared according to general procedure 2.1 using **1a** and **2b** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3ab** as yellow oil (60% yield). The <sup>1</sup>H NMR data matched those reported in the literature:<sup>1</sup> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.31-7.14 (m, 7H), 7.11-7.03 (m, 1H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.35 (d, *J* = 15.8 Hz, 1H), 5.95-5.82 (m, 1H), 3.18 (s, 3H), 2.72-2.58 (m, 2H), 1.42 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 143.1, 137.2, 133.6, 133.5, 128.4, 127.8, 127.2, 126.1, 124.2, 122.9, 122.4, 108.0, 77.3, 77.0, 76.7, 48.6, 41.6, 26.1, 22.5.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 8.5 min (minor), 10.2 min (major).

Optical Rotation:  $[\alpha]_D^{33}$  +4.6 (c 0.2, <sup>*i*</sup>PrOH) for 83% ee.



(E)-1,3-Dimethyl-3-(3-(p-tolyl)allyl)indolin-2-one (**3ac**)



**3ac** was prepared according to general procedure 2.1 using **1a** and **2c** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3ac** as yellow oil (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.25 (td, *J* = 7.6, 1.3 Hz, 1H), 7.23-7.20 (m, 1H), 7.11-7.02 (m, 5H), 6.81 (d, *J* = 7.7 Hz, 1H), 6.31 (d, *J* = 15.6 Hz, 1H), 5.90-5.75 (m, 1H), 3.17 (s, 3H), 2.69-2.57 (m, 2H), 2.29 (s, 3H), 1.41 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 143.1, 136.9, 134.5, 133.5, 129.1, 127.8, 126.0, 123.1, 122.9, 122.3, 107.9, 48.6, 41.6, 26.1, 22.5, 21.1; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>22</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 292.1696; found 292.1703.

(*E*)-3-(3-(4-Chlorophenyl)allyl)-1,3-dimethylindolin-2-one (**3ad**)

Exact Mass: 311.1077

**3ad** was prepared according to general procedure 2.1 using **1a** and **2d** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ad** as yellow oil (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.27 (td, *J* = 7.7, 1.3 Hz, 1H), 7.24-7.17 (m, 3H), 7.13-7.03 (m, 3H), 6.82 (m, 1H), 6.29 (d, *J* = 15.8 Hz, 1H), 5.90-5.79 (m, 1H), 3.18 (s, 3H), 2.64 (dd, *J* = 7.6, 1.1 Hz, 2H), 1.42 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 143.1, 135.7, 133.5, 132.8, 132.5, 128.6, 127.9, 127.3, 125.0, 122.9, 122.5, 108.1, 48.6, 41.6, 26.2, 22.6; HRMS: (ESI) calcd for C<sub>19</sub>H<sub>19</sub>CINO<sup>+</sup>[M+H]<sup>+</sup> 312.1150; found 312.1149.

(*E*)-3-(3-(4-Fluorophenyl)allyl)-1,3-dimethylindolin-2-one (**3ae**)



**3ae** was prepared according to general procedure 2.1 using **1a** and **2e** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ae** as yellow oil (70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.30-7.25 (m, 1H), 7.24-7.20 (m, 1H), 7.18-7.11 (m, 2H), 7.08 (td, *J* = 7.5, 0.9 Hz, 1H), 6.97-6.88 (m, 2H), 6.83 (d, *J* = 7.8 Hz, 1H), 6.30 (d, *J* = 15.8 Hz, 1H), 5.78 (dt, *J* = 15.4, 7.5 Hz, 1H), 3.18 (s, 3H), 2.70-2.58 (m, 2H), 1.42 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 163.3, 143.1,  $\delta$  133.4 (d, *J* = 3.3 Hz), 133.4, 132.5, 127.9, 127.6 (d, *J* = 7.9 Hz), 123.9 (d, *J* = 2.2 Hz), 122.9, 122.4, 115.3 (d, *J* = 21.5 Hz), 108.0, 48.7, 41.6, 26.2, 22.6; <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>)  $\delta$  -115.06; HRMS: (ESI) calcd for C<sub>19</sub>H<sub>19</sub>FNO<sup>+</sup>[M+H]<sup>+</sup> 296.1145; found 296.1439.

#### (E)-1,3-Dimethyl-3-(3-(4-(trifluoromethyl)phenyl)allyl)indolin-2-one (3af)



```
Chemical Formula: C<sub>20</sub>H<sub>18</sub>F<sub>3</sub>NO
Exact Mass: 345.1340
```

**3af** was prepared according to general procedure 2.1 using **1a** and **2f** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3af** as yellow oil (43% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.48 (d, *J* = 8.2 Hz, 2H), 7.30-7.26 (m, 2H), 7.25 (d, *J* = 2.4 Hz, 1H), 7.24-7.21 (m, 1H), 7.08 (td, *J* = 7.5, 1.0 Hz, 1H), 6.83 (d, *J* = 7.7 Hz, 1H), 6.36 (d, *J* = 14.8 Hz, 1H), 5.95 (dq, *J* = 15.9, 7.9 Hz, 1H), 3.18 (s, 3H), 2.72-2.65 (m, 2H), 1.43 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 173.8, 158.3, 143.2, 133.4, 132.5, 128.1, 127.2, 126.3, 125.5 (q, *J* = 3.8 Hz), 123.2, 122.9, 122.6, 108.2, 48.7, 41.7, 26.3, 22.7; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -62.4; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 346.1413; found 346.1419. (E)-1,3-Dimethyl-3-(3-(4-(methylsulfonyl)phenyl)allyl)indolin-2-one (3ag)



**3ag** was prepared according to general procedure 2.1 using **1a** and **2g** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ag** as yellow oil (41% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.82-7.76 (m, 2H), 7.36-7.32 (m, 2H), 7.31-7.27 (m, 1H), 7.23 (ddd, *J* = 7.4, 1.3, 0.5 Hz, 1H), 7.09 (td, *J* = 7.5, 1.0 Hz, 1H), 6.84 (d, *J* = 7.6 Hz, 1H), 6.39 (d, *J* = 15.8 Hz, 1H), 6.04 (ddd, *J* = 15.7, 8.0, 7.1 Hz, 1H), 3.18 (s, 3H), 3.02 (s, 3H), 2.75-2.65 (m, 2H), 1.44 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  179.8, 143.0, 142.6, 138.7, 133.2, 131.9, 128.9, 128.1, 127.6, 126.8, 122.8, 122.6, 108.1, 48.5, 44.5, 41.6, 26.2, 22.7; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>22</sub>NO<sub>3</sub>S<sup>+</sup>[M+H]<sup>+</sup> 378.1134; found 378.1126.

#### (*E*)-1,3-Dimethyl-3-(3-(m-tolyl)allyl)indolin-2-one (**3ah**)



**3ah** was prepared according to general procedure 2.1 using **1a** and **2h** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ah** as yellow oil (70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.27 (td, *J* = 7.7, 1.2 Hz, 2H), 7.24-7.21 (m, 1H), 7.13 (t, *J* = 7.5 Hz, 1H), 7.07 (td, *J* = 7.5, 0.9 Hz, 1H), 7.04-6.97 (m, 3H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.31 (d, *J* = 15.7 Hz, 1H), 5.95-5.83 (m, 1H), 3.19 (s, 3H), 2.71-2.55 (m, 2H), 2.29 (s, 3H), 1.41 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 143.1, 137.9, 137.2, 133.8, 133.6, 128.3, 128.0, 127.8, 126.9, 123.9, 123.2, 122.9, 122.4, 108.0, 77.3, 77.0, 76.7, 48.6, 41.6, 26.2, 22.5, 21.3; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>22</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 292.1696; found 292.1698.

(*E*)-1,3-Dimethyl-3-(3-(o-tolyl)allyl)indolin-2-one (**3ai**)



Chemical Formula: C<sub>20</sub>H<sub>21</sub>NO Exact Mass: 291.1623

**3ai** was prepared according to general procedure 2.1 using **1a** and **2i** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3ai** as yellow oil (70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.29-7.22 (m, 3H), 7.14 (dd, *J* = 7.3, 2.3 Hz, 1H), 7.10-7.04 (m, 4H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.49 (d, *J* = 15.6 Hz, 1H), 5.70 (dt, *J* = 15.4, 7.6 Hz, 1H), 3.18 (s, 3H), 2.68 (d, *J* = 7.8 Hz, 2H), 2.17 (s, 3H), 1.43 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 143.1, 136.6, 135.2, 133.5, 132.0, 130.0, 127.8, 127.1, 125.9, 125.8, 125.7, 122.9, 122.3, 108.0, 48.8, 41.9, 26.1, 22.7, 19.7; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>21</sub>NONa<sup>+</sup>[M+Na]<sup>+</sup> 314.1515; found 314.1511. (E)-1,3-Dimethyl-3-(3-(naphthalen-1-yl)allyl)indolin-2-one (3aj)



Chemical Formula: C<sub>23</sub>H<sub>21</sub>NO Exact Mass: 327.1623

**3aj** was prepared according to general procedure 2.2 using **1a** and **2j** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3aj** as yellow oil (72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.79 (dt, *J* = 3.9, 2.8 Hz, 2H), 7.70 (d, *J* = 8.1 Hz, 1H), 7.47-7.39 (m, 2H), 7.38-7.23 (m, 5H), 7.14-7.07 (m, 1H), 7.00 (d, *J* = 15.5 Hz, 1H), 6.80 (d, *J* = 7.7 Hz, 1H), 5.81 (dt, *J* = 15.3, 7.6 Hz, 1H), 3.17 (s, 3H), 2.88-2.66 (m, 2H), 1.48 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 143.2, 135.3, 133.5, 133.3, 131.6, 131.0, 128.3, 127.8, 127.6, 127.5, 125.8, 125.7, 125.5, 124.1, 123.8, 122.9, 122.4, 108.0, 77.3, 77.0, 76.7, 48.9, 42.0, 26.1, 22.7; HRMS: (ESI) calcd for C<sub>23</sub>H<sub>22</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 328.1696; found 328.1696.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 5.7 min (minor), 6.5 min (major).

Optical Rotation: [α]<sub>D</sub><sup>33</sup> +47.7 (*c* 0.2, /PrOH) for 84% ee.


S37

(E)-3-(3-(Benzo[d][1,3]dioxol-5-yl)allyl)-1,3-dimethylindolin-2-one (**3ak**)



Exact Mass: 321.1365

**3ak** was prepared according to general procedure 2.1 using **1a** and **2k** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3ak** as yellow oil (73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.29-7.23 (m, 1H), 7.21 (dd, *J* = 7.4, 1.2 Hz, 1H), 7.07 (td, *J* = 7.5, 1.0 Hz, 1H), 6.82 (d, *J* = 7.7 Hz, 1H), 6.71 (d, *J* = 1.7 Hz, 1H), 6.68 (d, *J* = 8.0 Hz, 1H), 6.63 (dd, *J* = 8.0, 1.7 Hz, 1H), 6.25 (d, *J* = 15.7 Hz, 1H), 5.90 (s, 2H), 5.69 (dt, *J* = 15.4, 7.5 Hz, 1H), 3.18 (s, 3H), 2.68-2.55 (m, 2H), 1.40 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.3, 147.9, 146.9, 143.2, 133.7, 133.3, 131.8, 127.9, 123.0, 122.5, 120.8, 108.2, 108.1, 105.5, 101.0, 48.8, 41.7, 26.2, 22.6; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>20</sub>NO<sub>3</sub><sup>+</sup>[M+H]<sup>+</sup> 322.1438; found 322.1443.

(*E*)-3-(3-(9-Ethyl-9*H*-carbazol-2-yl)allyl)-1,3-dimethylindolin-2-one (**3al**)



**3al** was prepared according to general procedure 2.1 using **1a** and **2l** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3al** as yellow oil (64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 (dd, *J* = 6.8, 0.8 Hz, 1H), 7.91 (d, *J* = 1.5 Hz, 1H), 7.44 (ddd, *J* = 8.2, 7.1, 1.2 Hz, 1H), 7.38-7.33 (m, 2H), 7.29-7.24 (m, 3H), 7.20 (ddd, *J* = 8.0, 7.2, 1.0 Hz, 1H), 7.12-7.05 (m, 1H), 6.84-6.79 (m, 1H), 6.52 (d, *J* = 15.7 Hz, 1H), 5.91 (ddd, *J* = 15.5, 8.0, 7.1 Hz, 1H), 4.32 (q, *J* = 7.2 Hz, 2H), 3.19 (s, 3H), 2.78-2.56 (m, 2H), 1.45 (s, 3H), 1.39 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  211.8, 174.6, 171.6, 170.8, 165.8, 165.2, 159.9, 159.1, 157.1, 155.5, 154.4, 154.4, 154.3, 153.7, 152.6, 151.8, 150.2, 149.6, 139.9, 139.7, 139.4, 80.2, 73.2, 68.9, 57.6, 53.8, 45.2; HRMS: (ESI) calcd for C<sub>27</sub>H<sub>26</sub>N<sub>2</sub>ONa<sup>+</sup>[M+Na]<sup>+</sup> 417.1937; found 417.1929. 3-(2-(1*H*-Inden-2-yl)ethyl)-1,3-dimethylindolin-2-one (**3am**)



Chemical Formula: C<sub>20</sub>H<sub>19</sub>NO Exact Mass: 289.1467

**3am** was prepared according to general procedure 2.1 using **1a** and **2m** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3am** as yellow oil (70% yield). H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.28-7.18 (m, 3H), 7.18-7.11 (m, 2H), 7.08 (td, *J* = 7.7, 0.9 Hz, 1H), 7.05-7.00 (m, 1H), 6.73 (d, *J* = 7.7 Hz, 1H), 6.32 (d, *J* = 0.7 Hz, 1H), 3.15 (d, *J* = 13.9 Hz, 1H), 3.11 (s, 3H), 2.95 (dd, *J* = 18.1, 15.1 Hz, 2H), 2.74 (d, *J* = 22.8 Hz, 1H), 1.47 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 144.8, 144.4, 143.3, 143.1, 133.6, 129.8, 127.9, 125.9, 123.8, 123.2, 122.7, 122.4, 120.2, 108.1, 49.3, 42.0, 39.5, 26.1, 24.2; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>20</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 290.1539; found 290.1546.

1,3-Dimethyl-3-((2*E*,4*E*)-5-phenylpenta-2,4-dien-1-yl)indolin-2-one (**3an**)



**3an** was prepared according to general procedure 2.1 using **1a** and **2n** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3an** as yellow oil (90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34-7.30 (m, 2H), 7.30-7.24 (m, 3H), 7.23-7.15 (m, 2H), 7.07 (td, *J* = 7.5, 1.0 Hz, 1H), 6.83 (d, *J* = 7.8 Hz, 1H), 6.64-6.52 (m, 1H), 6.39 (d, *J* = 15.7 Hz, 1H), 6.16 (ddd, *J* = 15.0, 10.4, 0.5 Hz, 1H), 5.46 (dt, *J* = 15.2, 7.6 Hz, 1H), 3.19 (s, 3H), 2.59 (d, *J* = 7.7 Hz, 2H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.3, 143.2, 137.4, 134.3, 133.7, 131.4, 128.7, 128.6, 128.6, 127.9, 127.4, 126.3, 123.0, 122.5, 108.1, 48.7, 41.6, 26.3, 22.7; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>22</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 304.1696; found 304.1689.

(*E*)-3-(3-(4-chlorophenyl)allyl)-1,3,5-trimethylindolin-2-one (**3bd**)



**3bd** was prepared according to general procedure 2.2 using **1b** and **2d** and was purified by silica gel column chromatography (PE/EA =  $40/1 \sim 5/1$ ) to obtain **3bd** as yellow oil (66% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.24-7.16 (m, 2H), 7.13-7.08 (m, 2H), 7.08-7.04 (m, 1H), 7.04-7.00 (m, 1H), 6.71 (d, *J* = 7.8 Hz, 1H), 6.30 (d, *J* = 15.7 Hz, 1H), 5.97-5.74 (m, 1H), 3.15 (s, 3H), 2.63 (dt, *J* = 7.1, 1.2 Hz, 2H), 2.35 (s, 3H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.0, 140.7, 135.7, 133.5, 132.7, 132.3, 131.9, 128.5, 128.1, 127.3, 125.1, 123.7, 107.7, 48.7, 41.7, 26.2, 22.6, 21.2; HRMS: (ESI) calcd for C<sub>20</sub>H<sub>20</sub>CINONa<sup>+</sup>[M+Na]<sup>+</sup> 348.1126; found 348.1116.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 5.1 min (minor), 5.6 min (major).

Optical Rotation:  $[\alpha]_{D^{33}}$  +51.4 (*c* 0.5, <sup>*i*</sup>PrOH) for 77% ee.





(*E*)-3-(3-(benzo[d][1,3]dioxol-5-yl)allyl)-1,3,5-trimethylindolin-2-one (**3bk**)



Exact Mass: 335.1521

**3bk** was prepared according to general procedure 2.2 using **1b** and **2k** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3bk** as yellow oil (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.09-7.02 (m, 2H), 6.73-6.66 (m, 3H), 6.66-6.60 (m, 1H), 6.26 (d, *J* = 15.5 Hz, 1H), 5.90 (s, 2H), 5.74-5.62 (m, 1H), 3.15 (s, 3H), 2.60 (d, *J* = 7.5 Hz, 2H), 2.36 (s, 3H), 1.39 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.2, 147.8, 146.8, 140.8, 133.7, 133.1, 131.9, 128.0, 123.7, 122.6, 120.7, 108.1, 107.7, 105.5, 100.9, 48.7, 41.6, 26.2, 22.6, 21.2; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>21</sub>NO<sub>3</sub>Na<sup>+</sup>[M+Na]<sup>+</sup> 358.1414; found 358.1390.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 80/20 as eluent, 254 nm, 1 mL/min. tR = 5.1 min (minor), 5.9 min (major).

Optical Rotation:  $[\alpha]_D^{31}$  +11.4 (*c* 0.1, <sup>*i*</sup>PrOH) for 81% ee.





3-((1*H*-inden-2-yl)methyl)-1,3,5-trimethylindolin-2-one (**2bm**)



**3bm** was prepared according to general procedure 2.2 using **1b** and **2m** and was purified by silica gel column chromatography (PE/EA = 40/1~5/1) to obtain **3bm** as yellow oil (62% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.24-7.20 (m, 1H), 7.19-7.11 (m, 2H), 7.08-7.06 (m, 1H), 7.06-7.00 (m, 2H), 6.62 (d, *J* = 7.9 Hz, 1H), 6.31 (s, 1H), 3.14 (d, *J* = 13.1 Hz, 1H), 3.09 (s, 3H), 2.97 (d, *J* = 22.1 Hz, 1H), 2.90 (d, *J* = 14.5 Hz, 1H), 2.76 (d, *J* = 22.1 Hz, 1H), 2.37 (s, 3H), 1.45 (s, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 144.9, 144.6, 143.4, 140.8, 133.7, 131.9, 129.6, 128.2, 125.0, 123.8, 123.5, 123.2, 120.2, 107.8, 49.3, 42.0, 39.6, 26.2, 24.4, 21.2; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>22</sub>NO<sup>+</sup>[M+H]<sup>+</sup> 304.1696; found 304.1688.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 4.9 min (minor), 5.6 min (major).

Optical Rotation: [α]<sub>D</sub><sup>33</sup> +56.2 (*c* 0.2, /PrOH) for 73% ee.







(E)-3-(3-(4-methoxyphenyl)allyl)-1,3,4-trimethylindolin-2-one (3qa)



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.15 (t, *J* = 7.8 Hz, 1H), 7.06-6.98 (m, 2H), 6.84 (d, *J* = 7.7 Hz, 1H), 6.76-6.69 (m, 2H), 6.67-6.61 (m, 1H), 6.26 (d, *J* = 15.6 Hz, 1H), 5.53-5.40 (m, 1H), 3.74 (s, 3H), 3.14 (s, 3H), 2.90-2.74 (m, 2H), 2.44 (s, 3H), 1.50 (s, 3H);<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  180.1, 158.8, 143.5, 134.0, 132.1, 130.2, 130.1, 127.6, 127.2, 125.0, 122.3, 113.7, 105.7, 55.2, 50.0, 39.7, 26.2, 21.5, 18.4; HRMS: (ESI) calcd for C<sub>21</sub>H<sub>23</sub>NO<sub>2</sub>H+ [M+H]+ 322.1802; found 322.1797.

The enantiomeric purity was established by HPLC analysis using a chiral column: AD-H column, 30 °C, *n*-Hexane/*i*-Propanol = 90/10 as eluent, 254 nm, 1 mL/min. tR = 8.2 min (minor), 9.2 min (major).



S47

## 5. Synthetic Applications<sup>2</sup>



Scheme S1. Formal total synthesis of (+)-physovenine and (+)-physostigmine.

**Procedure for the synthesis of the aldehyde intermediate 4**: To a solution of **3ca** (100 mg, 0.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub>/MeOH (3 mL/3 mL), O<sub>3</sub> was bubbled at -78 °C until the reaction was complete (monitored by TLC). Argon was bubbled into the solution for 5 min to remove the excess O<sub>3</sub>. PPh<sub>3</sub> was added at -78 °C and the mixture was kept stirring for another hour. The reaction mixture was passed through a short pad of silica gel, and eluted with EtOAc. The filtrate was concentrated and the residue was purified by flash column chromatography on silica gel (PE/ethyl acetate = 5/1 to 2/1) to afford the aldehyde intermediate **4** as a white solid (42.1 mg, 60% yield).

**Procedure for the synthesis of 5**: To a solution of LiAlH<sub>4</sub> (260  $\mu$ L, 0.65 mmol, 2.5 mol/L in THF) in dry THF (3 mL), the aldehyde intermediate **4** (15.1 mg, 0.065 mmol) was added under Ar, the mixture was stirred at room temperature for 40 min. The reaction was quenched by EtOAc and saturated aqueous NaHCO<sub>3</sub> successively. The phases were separated, the aqueous layer was extracted with EtOAc, and the combined organic extracts were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was

purified by silica gel column chromatography (PE/acetone/NEt<sub>3</sub> = 10/1/0.1) to afford **5** as a pale yellow oil (13.0 mg, 91%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.74-6.62 (m, 2H), 6.29 (d, *J* = 8.3 Hz, 1H), 5.03 (s, 1H), 4.03-3.86 (m, 1H), 3.75 (s, 3H), 3.47 (ddd, *J* = 10.9, 8.6, 5.4 Hz, 1H), 2.88 (s, 3H), 2.13 (ddd, *J* = 11.8, 5.3, 1.5 Hz, 1H), 2.09-1.99 (m, 1H), 1.45 (s, 3H); [ $\alpha$ ]<sub>D</sub><sup>30</sup> +24 (*c* 0.25, EtOH), literature value [ $\alpha$ ]<sub>D</sub><sup>22</sup> -81.2 (*c* 0.6, EtOH) for the opposite enantiomer.<sup>3</sup>

**Procedure for the synthesis of 6**: To a solution of the aldehyde intermediate **4** (15.1 mg, 0.065 mmol) and TEA (90 µL, 0.65 mmol) in anhydrous THF (3 mL), MeNH<sub>2</sub>·HCl (43.9 mg, 0.65 mmol) and MgSO<sub>4</sub> (50 mg) was added under Ar, the mixture was stirred at room temperature for 16 h. Then LiAlH<sub>4</sub> (260 µL, 0.65 mmol, 2.5 mol/L in THF) was added and the mixture was refluxed at 80 °C for 1.5 h. The reaction was quenched by EtOAc and saturated aqueous NaHCO<sub>3</sub> successively. The phases were separated, the aqueous layer was extracted with EtOAc, and the combined organic extracts were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by silica gel column chromatography (PE/acetone/NEt<sub>3</sub> = 8/1/0.1) to afford **6** as a pale yellow oil (12.8 mg, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.65 (dt, *J* = 4.0, 2.4 Hz, 2H), 6.36 (d, *J* = 8.2 Hz, 1H), 4.05 (s, 1H), 3.75 (s, 3H), 2.89 (s, 3H), 2.73 (dt, *J* = 9.5, 5.4 Hz, 1H), 2.68-2.60 (m, 1H), 2.54 (s, 3H), 1.95 (dd, *J* = 7.4, 5.4 Hz, 2H), 1.43 (s, 3H); [ $\alpha$ ]<sub>D</sub><sup>30</sup> +62 (*c* 0.2, MeOH), literature value [ $\alpha$ ]<sub>D</sub><sup>22</sup> -98 (*c* 1.0, MeOH) for the opposite enantiomer.<sup>3</sup>

# 6. Copies of the <sup>1</sup>H, <sup>19</sup>F and <sup>13</sup>C NMR spectra

3aa



<sup>210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10</sup> fl (ppm)





S52



3da

lyx-6-109-1-S-4-F&PMP

—-120.83

Me PMP =0 Ń Me Chemical Formula: C<sub>20</sub>H<sub>20</sub>FNO<sub>2</sub> Exact Mass: 325.1478





10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)







3ha





S60



3ka

S61



3la

#### 3ma



#### 3na



#### 3oa



### 3ра

 $\int$ 1111 5 5 5 5 Me \_\_\_\_\_PMP ≻o Ν. Bn Chemical Formula: C<sub>26</sub>H<sub>25</sub>NO<sub>2</sub> Exact Mass: 383.1885 0.98-0.974 1.37 5.91 1.03 1.03 1.93 1.93 0.95 -79.0 3.00-3.03H -98-9.0 8.5 8.0 7.5 7.0 6.5 5.5 5.0 4.0 3.5 f1 (ppm) 6.0 4.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0-0.5 -1.0 -1 -168.94 -168.94 -142.27 -142.27 -133.51 -133.51 -133.25 -133.25 -133.25 -123.66 -133.25 -122.66 -127.43 -127.03 -127.03 -127.04 -127.0 lyx-6-109-3-S-N-Bn& 55.33
49.02
43.66
41.95 -- 23.43 - 180. ì Me // PMP -0 ٠Ń Bn Chemical Formula: C26H25NO2 Exact Mass: 383.1885 210 200 190 180 170 160 150 140 130 120 110 100 90 fl (ppm) 80 70 60 50 40 30 20 10 0 -10

### 3ab

11111 Ме Chemical Formula: C<sub>19</sub>H<sub>19</sub>NO Exact Mass: 277.1467 7.36 1.05 0.97 F76.0 <u>F86.0</u> 2.01H 3.06<sub>T</sub> 3.00<sub>H</sub> 4.0 3.5 f1 (ppm) 4.5 1.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.03.0 2.5 2.0 1.0 0.5 0.0 -0.5 -1.0 77.32 CDCI3 77.00 CDCI3 76.68 CDCI3 lyx-6-13-1-S&Ph 143.07 137.20 133.51 133.51 133.51 128.37 128.37 128.37 128.37 127.15 127.15 122.91 122.91 122.36 107.96 - 26.14 - 22.51 0 М̀е Chemical Formula: C<sub>19</sub>H<sub>19</sub>NO Exact Mass: 277.1467

210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 fl (ppm)











3ae

lyx-6-155-02-S&4-F-Ph

=0 Me Chemical Formula: C<sub>19</sub>H<sub>18</sub>FNO Exact Mass: 295.1372






220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)



3ah







220 210 200 190 180 170 160 150 140 130 120 110 100 90 f1 (ppm)



230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 fl (ppm)

## 3am



S79

## 3an



3bd





3bk

## 3bm







## 7. References

(a) Gao, S.; Liu, H.; Wu, Z.; Yao, H.; Lin, A. *Green Chem.* 2017, *19*, 1861; (b) Liu,
X.; Gu, Z. *Org. Chem. Front.* 2015, *2*, 778.

2. (a) Zhou, B.; Hou, W.; Yang, Y.; Feng, H.; Li, Y. Org. Lett. 2014, 16, 1322. (b) T.

Wang, W. Yao, F. Zhong, G. Pang, Y. Lu. Angew. Chem. Int. Ed. 2014, 53, 2964.

3. Q. Yu, W. Luo, Y. Li, *Heterocycles*, **1993**, 36, 1279.